济民健康管理股份有限公司

Core Viewpoint - The company has announced its third-quarter financial report, emphasizing the accuracy and completeness of the information provided by its board and management, while also detailing its share repurchase plan and ongoing legal issues related to a fraud case [2][6][7]. Financial Data - The financial report for the third quarter is unaudited, and the company has provided key financial data and indicators in RMB [3][8]. - As of September 30, 2025, the company has repurchased a total of 2,005,500 shares, with a total expenditure of 12.089 million RMB (excluding transaction fees) [7]. Share Repurchase Plan - The company plans to repurchase shares using its own funds through centralized bidding, with a maximum price of 10.00 RMB per share and a total repurchase amount between 100 million RMB and 200 million RMB, to be completed within 12 months from the board's approval [6][7]. Legal Issues - The company is currently facing 14 lawsuits from primary distributors involving a total of 69.5026 million RMB, and 10 lawsuits from secondary distributors involving 17.0766 million RMB, related to a case of forgery involving a former employee [7].